Flu Hospitalization Rate Week 22: Market Calls It

The flu season is winding down, and the prediction market for Week 22 hospitalization rates has essentially closed the book early. Traders have priced this contract at 97% for the 85-90 range, leaving almost no room for surprise. Here’s what the measurements are telling us: late-season flu activity typically collapses in late May and early June, and the CDC’s FluView data has been tracking that familiar seasonal pattern.

The market question asks where the influenza hospitalization rate will land in Week 22 of 2026, defined as the week ending June 12, 2026. The YES price sits at 0.97, the NO price at 0.03, and total volume is just $1,277. This is a thin market, and thin markets can move sharply on new data.

How This Flu Hospitalization Contract Works

The CDC publishes weekly influenza hospitalization rates through its FluView surveillance system. Resolution depends on where the Week 22 cumulative hospitalization rate falls across the defined outcome bands.

• The 85-90 band is priced at 0.97, implying a 97% probability of resolution in that range.
• Alternative outcomes including below 80, 80-85, 90-95, 95-100, and 100-plus each carry negligible implied probability.

For any alternative band to pay out, the CDC FluView Week 22 report would need to show hospitalization rates landing outside the 85-90 window. Late-season flu data rarely produces the kind of surge that would push rates above 90. A sharp unseasonal outbreak or a late-breaking strain variant would be the primary scenario. The data doesn’t care about the politics, and the data says late June flu hospitalizations trend firmly downward.

Sponsored Partner

Momentum and Market Signals

The momentum composite here is essentially flat. The one-hour price change is zero, the trend score sits at 27.08, and no significant directional pressure has touched this contract. The market is not pricing uncertainty, not science. It has already reached a conclusion and stopped moving.

Total 24-hour volume is $1,277, which is the entire volume this contract has ever seen. Liquidity is $12,653, which is thin. A single moderately-sized trade could shift the price meaningfully before the June 12 resolution date. That is worth keeping in mind even though the 97% probability suggests the outcome is settled.

Key Factors

• The one-hour and 24-hour price changes both register at zero, confirming the contract has found a stable equilibrium at 97%.
• CDC FluView publishes Week 22 data on a weekly schedule, and that release is the single event that will determine resolution.
• Total volume below $1,277 means this market has attracted minimal participation, and the price reflects a small number of trader positions rather than broad market consensus.
• Seasonal flu patterns in the Northern Hemisphere consistently show hospitalization rates declining through late May and June, which anchors the 85-90 band as the expected landing zone.
• No whale trades have registered in this contract, so there is no large-capital signal to interpret.

Lines Analysis: The CDC Data Will Decide

The CDC FluView system is the authoritative source here. Week 22 hospitalization data reflects activity from a period when flu season is historically at its weakest. Influenza A and B circulation typically bottoms out by late May in the US, and the cumulative hospitalization rate stabilizes in a narrow band during this period. The 85-90 range the market favors aligns with where late-season rates have landed in comparable years.

The meaningful risk for any alternative outcome comes from two directions. An unexpected late-season surge driven by a novel influenza variant could push rates above 90. A sharper-than-expected decline in activity could push rates below 85. Neither scenario has supporting evidence in current CDC surveillance data, which is why the market has priced them into the floor.

Signals to Monitor

• The CDC FluView Week 22 report, expected the week of June 12, is the only event that triggers resolution and the only data point that matters now.
• Any CDC Health Alert Network advisory about unusual influenza activity in late May or early June would reprice this contract immediately.
• WHO Global Influenza Surveillance and Response System updates on circulating strains could signal whether a late variant is gaining traction.
• State-level emergency department data from health departments in high-population states would be an early signal ahead of the federal FluView release.
• A significant change in CDC’s ILINet outpatient data for Week 21 would provide directional evidence for Week 22 hospitalization rates.

Total volume of $1,277 is very low. The 97% price reflects strong directional conviction from a small pool of traders. The CDC data favors the 85-90 band based on seasonal patterns, but the thin liquidity means this contract is not a reliable signal of broad market wisdom. The resolution date of June 12 is close, which limits the window for new information to change the picture.

LINES VERDICT

NEAR-CERTAIN RESOLUTION IN FAVORED BAND

Seasonal flu patterns and current CDC surveillance data align with the 85-90 hospitalization rate band. The market has priced this outcome at near-certainty, and the underlying epidemiology supports that conclusion.

What the market says: At 97% implied probability, traders have treated this as a settled question. The June 12 resolution date leaves almost no window for a data surprise to reprice the contract, but thin liquidity means even a small volume of new trades could shift the price.

Key unknown: The CDC FluView Week 22 report is the single data release that determines resolution. Any unexpected spike in influenza hospitalization activity between now and June 12 would be the only credible path to a different outcome.